36 results about "Anti-nuclear antibody" patented technology

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in the differential diagnosis of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample both the concentration of anti-CCP and of antinuclear antibodies (ANA) correlating the concentrations determined to the diagnosis of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and ANA and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and ANA in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

The invention relates to an antrodia camphorate cyclohexanedione compound used for treating autoimmune diseases and a medical composition thereof. The antrodia camphorate cyclohexanedione compound is about 4-hydroxyl-2, 3-dimethoxy-6-methyl-5(3, 7, 11-trimethyl-2, 6, 10-dodecatrien)-2-cyclohexanedione which is separated from antrodia camphorate extract and can relieve systemic erythromelalgia lupus and other symptoms caused by autoimmune diseases. Antrodia camphorate cyclohexanedione in the invention can reduce the content of urine protein of the mammalians with systemic erythromelalgia lupus and the thickness of the antinuclear antibody in blood, relieves kidney inflammation and lesion, lowers the harm of antinuclear antibody on autogenous tissues, and achieves the effect of treating autoimmune diseases such as systemic erythromelalgia lupus, and the like, and the diseases related to kidney by using natural materials without side effects.

The invention relates to the technical field of enzyme linked immune, and discloses a composition for an enzyme linked immunosorbent assay kit, an anti-nuclear antibody spectrum detection kit and a preparation method thereof. The composition comprises sealing liquid and ELISA diluents; the sealing liquid contains casein, saccharose, PBS, mannitol, Tween20, lycine and sodium azide; the ELISA diluents contain PBS, casein, sodium p-hydroxybenzoate, PEG, lycine and Proclin300. By starting from the sealing liquid and the ELISA diluents of the enzyme linked immunosorbent assay kit, the proper ingredients are selected, so that the enzyme linked immunosorbent assay kit can maintain the detection stability for a long time. Meanwhile, the anti-nuclear antibody spectrum detection kit prepared from the composition has higher stability; the guarantee period is 2 years or more.

The invention discloses a method for detecting the core fucosylation level of serum IgG. The method comprises a step of specifically identifying core fucosyl groups in the serum IgG by using lectin, but not comprises a step of sampling from an organism, and a serum sample is an in vitro sample. The lectin is an Aspergillus oryzae lectin AOL protein (domain) which can specifically identify the corefucosyl groups, and is obtained by prokaryotic expression, and the amino acid sequence of the lectin is represented by SEQ ID NO. 1; and the lectin is encoded by an FleA gene fragment represented bySEQ ID NO. 2. The method has potential application values in the screening of autoimmune diseases and the detection of the autoimmune diseases and provides a potential therapeutic way for possible immune regulation intervention after being combined with clinical anti-nuclear antibody titer detection.

The invention discloses an antinuclear antibody combined detection kit which comprises a sample diluent, an enzyme conjugate, a washing fluid and a substrate. The invention also discloses a detection method using the antinuclear antibody combined detection kit. The detection method comprises balancing the detection kit to room temperature, processing a sample, rinsing a membrane surface in a card window, adding the sample and the washing fluid, adding the enzyme conjugate, developing, terminating, and the like. By using the kit and the method, multichannel multi-sample detection can be performed at the same time (that is, 16 antinuclear antibody detection projects can be performed at the same time, and 16 independent detection results can be provided), and the sensitivity can reach the detection level of an immunoblotting product and is far higher than the detection level of a dot immunogold filtration product; and the detection time of the kit is close to the detection time of dot immunogold filtration method and is far better than the detection time of an immunoblotting method, does not need reagent concentrate processing, warm bath, repeated cleaning and the like, and extremely well satisfies clinical usage.

The invention discloses a preparation method of a human antinuclear antibody, comprising the following steps: collecting single nuclear cells of peripheral blood of a patient with the autoimmune disease, extracting the total RNA (Ribonucleic Acid), and carrying out reverse transcription to obtain a cDNA (Complementary Deoxyribonucleic Acid) library; amplifying a light chain k,1 gene and an immunoglobulin molecule heavy chain Fd gene by taking the acquired cDNA library as a template through a PCR (Polymerase Chain Reaction) method; cloning the light chain k,1 gene into a pComb3Hss carrier to construct a light chain library; loading the heavy chain Fd gene into a carrier to construct and finish a combinatorial library; transforming the obtained recombinant plasmid into escherichia coli XL1-Blue, infecting by using a helper phage M12KO7, and expressing the random combinatorial library on the surface of a filamentous phage to finish phage surface display; and purifying the Fab segment of the human antinuclear antibody by utilizing affinity chromatography. By using the preparation method, the defects that the random combinatorial antibody library has strong randomness, the screening workload is large and a specific antibody is not easy to obtain are overcome, and the specific antibody can be directly screened from a phage antibody library; and in addition, the method is simple and feasible, and the experimental period is shortened.

The invention discloses stable preservation diluent, anti-nuclear antibody detection reagent for the stable preservation diluent, a preparation method thereof and an anti-nuclear antibody detection kit of the anti-nuclear antibody detection reagent. The pH of the stable preservation diluent is 5-8, and the stable preservation diluent includes a buffer solution, salt, osmotic substances and a preservative; the osmotic substances are selected from at least one substance of polyol, methylamine and amino acid. The anti-nuclear antibody detection reagent suspends a coupling matter of anti-nuclear antibody target antigens and magnetic microspheres in the stable preservation diluent for storage to stably store the diluent including the buffer solution, the salt, the osmotic substances and the preservative, thereby providing the coupling matter of the anti-nuclear antibody target antigens and the magnetic microspheres with a stable liquid storage environment.

Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, antinuclear antibodies (ANA), anti-Smith antibodies (anti-Sm) and optional rule-out markers (SS-B/La, Scl-70, Jo-1, CENP, MCV).

The invention discloses an antigen-immobilized matrix membrane, a kit comprising the same for detecting an antinuclear antibody spectrum related to autoimmune diseases and purpose thereof. The antigen-immobilized matrix membrane comprises but not only comprises following 22 mutually independent antigen detection lines including double-stranded DNA, histone, ribosome P0 protein, PCNA, SmD1, SmD3, SmB/B', snRNP-A, snRNP-C, snRNP68/70, SSA/Ro60, SSA/Ro52, SSB/La, Jo-1, PL-7, PL-12, PmScl, Scl-70, CENP-A, CENP-B, RA33 and PR3. When the kit containing the antigen-immobilized matrix membrane is usedfor detection, 22 kinds of autoimmune antibodies can be detected simultaneously; and thus diagnosis of eight kinds of common diffuse connective tissue diseases is assisted.

The invention discloses an antinuclear antibody chemiluminescence immunoassay kit and a preparation method thereof. The antinuclear antibody chemiluminescence immunoassay kit comprises antinuclear antibody monoclonal antibody-coated chloracetylated magnetic particles and an inhibin monoclonal antibody-labelled chemiluminescent marker. With a full-automatic chemiluminescence immunity analyzer as a testing tool, the antinuclear antibody chemiluminescence immunoassay kit can complete detection of antinuclear antibodies. Through experiments, detection sensitivity of the antinuclear antibody chemiluminescence immunoassay kit reaches 4 AU/mL. In comparison with sensitivity of a traditional antinuclear antibody detection method, the sensitivity of the invention is raised by at least 10 times. Detection precision of the antinuclear antibody chemiluminescence immunoassay kit is high.

The invention discloses a combined medication method of prednisone and aspirin and application of the method to preparation of a combined medicine for treating anti-nuclear antibody positive infertility. According to the scheme of the invention, prednisone and aspirin are used to perform combined medication to treat the anti-nuclear antibody positive infertility in three months before ovulation induction. Through comparison treatment, the fertility rate, the planting rate and the pregnancy rate in a treatment group are higher than those in a non-treatment group, and the abortion rate in the non-treatment group is higher. Through comparison on IVF-ET between the cycle and the last cycle in the treatment group, the outcome indicates that the fertility rate, the planting rate and the pregnancy rate in the treatment cycle are higher than those in the last non-treatment cycle, and the abortion rate in the cycle after treatment is lower. By adoption of the scheme of the invention, the prednisone serving as immunosuppression is used in three months before ovulation induction to serve as anticoagulation aspirin treatment, so that the reproductive outcome of the anti-nuclear antibody positive women can be improved.

The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.

The present invention discloses a pharmaceutical composition for treating a subject with immunological recurrent spontaneous abortion which comprises a therapeutically effective amount of a substance capable of lowering the in vivo level of antinuclear antibody. Particularly, the substance is chromosome No. 2 or fragment thereof containing fibronectin encoding gene derived from the spouse of said subject, or a mixture of chromosome No. 2 or fragment thereof containing fibronectin encoding gene derived from a plurality of males. The present invention also discloses a method for treating immunological recurrent spontaneous abortion.

The invention relates to application of rotenone in the preparation of a medicine for treating systemic lupus erythematosus and belongs to the field of Chinese medicine production. Rotenone can inhibit generation of antinuclear antibodies for lupus mice, alleviate myocardial damage of lupus mice, inhibit abnormal activation of B lymphocyte and splenomegaly for lupus mice and inhibit formation of lymph node tumor for lupus mice. Therefore, the invention provides a new candidate drug for treating systemic lupus erythematosus.